Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01258933 · ClinicalTrials.gov registry record · Phase 2
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01258933: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01258933 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01258933, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find out if ofatumumab can control CLL or SLL that is left after chemotherapy or chemoimmunotherapy. The safety of the drug will also be studied.
Interventions
- DRUG Ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-07-06 |
| Est. Completion | 2024-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01258933
The ClinicalTrials.gov registry entry for NCT01258933 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ofatumumab is the first listed.
NCT01258933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01258933 about?
NCT01258933 is a clinical study titled "Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy". The goal of this clinical research study is to find out if ofatumumab can control CLL or SLL that is left after chemotherapy or chemoimmunotherapy. The safety of the drug will also be studied.
What is the current status of trial NCT01258933?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2011-07-06. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT01258933?
The interventions under investigation include: Ofatumumab (DRUG).
Who is sponsoring clinical trial NCT01258933?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.